Table 1.
Patient characteristics.
| Characteristics | Distribution |
|---|---|
| Initial therapy response | |
| Partial response (Abs.; %) | 25 (65.79%) |
| Stable or progressive disease (Abs.; %) | 13 (34.21%) |
| Age at diagnosis | |
| Median (1st–3rd quartiles) | 70.27 (69.05–75.60) |
| Gender | |
| Female (Abs.; %) | 13 (34.21%) |
| Male (Abs.; %) | 25 (65.79%) |
| Comorbidity | |
| <1 (Abs.; %) | 9 (23.68%) |
| >1 (Abs.; %) | 17 (44.74%) |
| Nan (Abs.; %) | 12 (31.58%) |
| Asbestos exposure | |
| Yes (Abs.; %) | 12 (31.58%) |
| No (Abs.; %) | 9 (23.68%) |
| Nan (Abs.; %) | 17 (44.74%) |
| Smoking habit | |
| Yes (Abs.; %) | 8 (21.05%) |
| No (Abs.; %) | 12 (31.58%) |
| Ex (Abs.; %) | 5 (13.16%) |
| Nan (Abs.; %) | 13 (34.21%) |
| Pack/year | |
| ≤31 | 17 (44.74%) |
| >31 | 8 (21.05%) |
| Nan (Abs.; %) | 13 (34.21%) |
| Histology | |
| Non-epithelioid/biphasic (Abs.; %) | 9 (23.68%) |
| Epithelioid (Abs.; %) | 29 (76.31%) |
| Disease stage | |
| I | 0 (-) |
| II | 7 (18.42%) |
| III | 28 (73.69%) |
| IV | 3 (7.89%) |
| Pleural effusion | |
| Yes (Abs.; %) | 9 (23.68%) |
| No (Abs.; %) | 14 (36.84%) |
| Nan (Abs.; %) | 15 (39.47%) |
| ECOG | |
| 0–1 (Abs.; %) | 28 (73.68%) |
| 2 (Abs.; %) | 10 (26.32%) |
| BMI | |
| Overweight (Abs.; %) | 14 (36.84%) |
| Normal (Abs.; %) | 12 (31.58%) |
| Nan (Abs.; %) | 12 (31.58%) |
| Systemic therapy | |
| Ipi-nivo (Abs.; %) | 9 (23.68%) |
| Platinum-pem (Abs.; %) | 15 (39.47%) |
| Platinum-pem-beva (Abs.; %) | 7 (18.42%) |
| Platinum-pem-beva-atezo (Abs.; %) | 5 (13.16%) |
| Platinum-pem-pembro (Abs.; %) | 2 (5.27%) |
Ipilimumab (Ipi); Nivolumab (Nivo); Pemetrexed (Pem); Bevacizumab (Beva); Pembrolizumab (Pembro); Atezolizumab (Atezo). Not Available (NA); Body Mass Index (BMI).